Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    

Vanderbilt Research Explores Repositioning Existing Drugs to Prevent Epidemics

Donald Rubin, MD

Emerging viral infections like Zika keep popping up around the world in such quick succession that medicine is having a hard time keeping up. It can take 15 years and more than $1 billion to bring a new drug to market.

One possible solution: Identify the anti-viral potential of drugs for other diseases that are already on the market, and "reposition" them to stop epidemics before they start.

That's the approach a research team at Vanderbilt University School of Medicine is advocating. In a report published in the journal PLOS Computational Biology, Donald Rubin, MD, Zhongming Zhao, PhD, and colleagues describe how they used computer-based screening methods to identify 110 potential anti-viral drug targets.

The researchers said the anti-viral potential of approved drugs must, of course, be confirmed through animal and clinical testing, but "the prospect of drug repositioning is emerging as a promising alternative to traditional drug design," especially in combating infectious diseases, the team concluded.

Rubin, professor of Medicine and of Pathology, Microbiology and Immunology at Vanderbilt, is co-senior author of the paper with Zhao, a former Vanderbilt faculty member now at the University of Texas Health Science Center in Houston.

Viruses must hijack factors in the cells they infect in order to make copies of themselves. They're wily opponents, capable of mutating rapidly to slip through the body's immune defenses ... but they could be thwarted if the host factors they depend upon are identified and blocked.

About a dozen years ago at Vanderbilt, Rubin and colleague H. Earle Ruley, PhD, developed a technique for identifying the viral "Achilles' heel." Called gene-trap insertional mutagenesis, it's a way to identify genes in host cells that are essential for viral replication. Bits of DNA are inserted randomly throughout the cell's genome. If insertion occurs in a normally hijacked gene, the virus can't use it anymore because it's mutated or "trapped." Infected cells normally are lysed or blown apart by mushroom clouds of replicating virus. But those with a trapped gene survive.

In this way, the researchers were able to identify approximately 700 host genes that play a role in the replication of 10 distinct mammalian viruses including rhinovirus, Herpes simplex, HIV, polio, and the West African hemorrhagic viruses Marburg and Ebola.

Using bioinformatics analysis, they looked for those with known "drug-gene signatures," gene-expression responses to drug exposures. The result: 110 host genes that encode proteins already targeted by FDA-approved or investigational drugs or pre-clinical agents. Seven of the drugs could potentially be repositioned to target host proteins hijacked by Ebola, including the anti-arrhythmic drug ajmaline, the diuretic clopamide and the anti-inflammatory piroxicam (Feldene).


Related Articles:

Recent Articles

Cancer Care on the Cutting Edge

Nashville physician-scientists are helping lead the way in advancing cancer care.

Read More

The Evolution of Senior Living

The senior living industry is undergoing a makeover as baby boomers shift focus from medical-directed care to hospitality-driven services.

Read More

When Basic Science Becomes a Breakthrough

Noted immunologists joined forces at the recent International Cancer Immunotherapy Conference to discuss the importance of fostering and funding basic science.

Read More

Dr. Meredith McKean Brings New Hope, More Options for Melanoma Patients

Oncologist Meredith McKean, MD, MPH, overseeing Sarah Cannon's Melanoma Research Program

Read More

ONcology Rounds

News of note in cancer research, treatment and partnerships.

Read More

Ascension Saint Thomas Opens Cancer Center

Ascension Saint Thomas recently celebrated the grand opening of their comprehensive new cancer center on the Midtown campus.

Read More

NMGMA 10 Minute Takeaway

Medicare Part B representative from Palmetto GBA offered updates and resources to navigate compliance.

Read More

Improving Quality, Lowering Cost of Care for Seniors

Five years into the Medicare Shared Savings Program, more and more ACOs are beginning to demonstrate the ability to improve quality while lowering costs.

Read More

Planning Ahead: Patients & Power of Attorney

The time to think about a durable power of attorney is long before it's needed. Barbara Moss discusses the importance of the document in healthcare.

Read More

Council on Aging Honors Middle Tennesseans

The Council on Aging (COA) of Middle Tennessee hosted their 27th Annual Sage Awards on Oct. 29. With a belief that aging should be celebrated and embraced and that older adults have a lifetime of wisdom and experience to offer communities, the Sage Awards are presented each year to older adults who have made outstanding contributions to Middle Tennessee.

Read More

Email Print



Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: